News-Medical.Net July 31, 2024
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of its fourth generation CHO Edge System. With an increased typical titer range of 5-11 g/L across modalities before any upstream process optimization, the new system has been developed to optimize expression across a breadth of biologic architectures and increase the likelihood of high titer cell lines.
The system’s improved robustness has allowed Asimov to increase its minimum CLD titer guarantee for IgG monoclonal antibodies to 5 g/L. If the lead clone does not hit this benchmark, it is still transferred to the partner, but the service fee and all commercial use license fees are waived.
The 4th generation CHO Edge System updates expression...
Today's Sponsors
Today's Sponsor